BioCentury
ARTICLE | Company News

Vectura acquiring Skyepharma

March 17, 2016 1:04 AM UTC

Vectura Group plc (LSE:VEC) is acquiring fellow inhaled respiratory drug play Skyepharma plc (LSE:SKP) in a stock deal that values Skyepharma at about L441.3 million ($634.2 million).

The deal combines Skyepharma's dry powder and metered dose inhaler technologies with Vectura's dry powder inhalers and smart nebulization products. ...